Ronald C JR Renaud
CIK 1354434 · CEO & President · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$653.9K
Companies
11
Total Filings
55
Lifetime Open-Market Net
-$34.19M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| UPB | Director | — | $6.40 | — | $0 | 3 | 2026-06-11 |
| KLRA | CEO & President | 38,094 | $16.74 | $637.7K | $0 | 2 | 2026-06-11 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | President & CEO | 244,309 | $44.96 | $10.98M | $2.01M | 4 | 2024-01-23 |
| ATRA | Director | 1,260 | $7.81 | $9.8K | $0 | 3 | 2022-06-27 |
| ImageneBio, Inc. (IKNA) Delisted | Director | — | $17.16 | — | $0 | 2 | 2022-06-13 |
| Translate Bio, Inc. (TBIO) Delisted | Chief Executive Officer | 0 | $0.00 | $0 | -$36.25M | 9 | 2021-09-14 |
| CHIMERIX INC (CMRX) Delisted | Director | — | $8.54 | — | $0 | 6 | 2019-06-24 |
| AKBA | Director | 5,000 | $1.27 | $6.3K | $59.6K | 6 | 2018-06-15 |
| PTCT | Director | — | $75.39 | — | $0 | 3 | 2017-01-05 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | President & CEO | 89,990 | — | — | $0 | 14 | 2014-08-05 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Chief Financial Officer | 94,027 | — | — | $0 | 2 | 2007-02-16 |
Recent Filings · Page 2 of 6
55 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-27 | ATRA | Grant (A) | +20,500 | $0 | EDGAR |
| 2022-06-13 | ImageneBio, Inc. (IKNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-23 | ImageneBio, Inc. (IKNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-09-14 | Translate Bio, Inc. (TBIO) Delisted | Sell (S) | −954,053 | -$36.25M | EDGAR |
| 2021-09-14 | Translate Bio, Inc. (TBIO) Delisted | Exer (M) | +9,026 | $66.7K | EDGAR |
| 2021-06-09 | ATRA | Grant (A) | +11,000 | $0 | EDGAR |
| 2021-04-09 | Translate Bio, Inc. (TBIO) Delisted | Exer (M) | +9,026 | $66.7K | EDGAR |
| 2021-03-09 | Translate Bio, Inc. (TBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-14 | Translate Bio, Inc. (TBIO) Delisted | Exer (M) | +5,639 | $41.7K | EDGAR |
| 2020-11-18 | Translate Bio, Inc. (TBIO) Delisted | Exer (M) | +53,007 | $391.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.